Spinocerebellar ataxias (SCAs) are a group of dominantly inherited, ultra-rare, progressive neurodegenerative disorders characterized by gait disturbances, loss of motor coordination and balance, challenges with speech and swallowing, cognitive impairment, and decline in overall quality of life. There are more than 40 known SCA genotypes, with SCA1, SCA2, SCA3, and SCA6 being the most common worldwide. Biohaven, Ataxia UK and the National Ataxia Foundation are conducting a global study to better understand the lived experiences, disease burden, and unmet needs of people with SCA (PWSCA) and their caregivers, with the goal of informing future care approaches and therapeutic development.